China
Africa
Explore chapters and articles related to this topic
Clinical Studies In Acute and Chronic Inflammation
Published in Siegfried Matzku, Rolf A. Stahel, Antibodies in Diagnosis and Therapy, 2019
Anti-gamma interferon: In a mouse model of SLE, mice were treated from 16 weeks until 35 weeks with soluble interferon-gamma receptor or anti-IFN-gamma mAb the mice and remained alive 4 weeks post therapy in contrast to control mice where 50% died over the same time interval (Ozmen et al., 1995).
Toxicoproteomics reveals an effect of clozapine on autophagy in human liver spheroids
Published in Toxicology Mechanisms and Methods, 2023
Catherine Nury, Celine Merg, Yvan Eb-Levadoux, David Bovard, Matthieu Porchet, Fabio Maranzano, Isidora Loncarevic, Shahrzad Tavalaei, Eleonore Lize, Ramona Liliana Demenescu, Hasmik Yepiskoposyan, Julia Hoeng, Nikolai V Ivanov, Kasper Renggli, Bjoern Titz
Evaluation of the protein changes upon TNFα + IL-1β treatment by GSA indicated the expected perturbation of several immune-related gene/protein sets, including cytokine, inflammasome, and innate immune cell-related gene/protein sets (Supplementary Table 2). Most of the protein levels affected by TNFα + IL-1β treatment did not significantly change upon clozapine treatment (Figure 2(B)), suggesting that clozapine did not induce a broad inflammatory response in liver spheroid cultures. However, interferon gamma receptor 1 (IFNGR1) was significantly upregulated by both TNFα + IL-1β and 60 µM clozapine treatment. IFNGR1 upregulation in the liver has been observed upon exposure to liver toxicants (Jellali et al. 2021), and IFN-γ has been found to affect the fate of hepatocytes (Horras et al. 2011). Insulin-like growth factor-binding protein 1 (IGFBP1) was strongly upregulated by both treatments. IGFBP1 is associated with autophagy regulation (Galluzzi et al. 2014).
Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2
Published in OncoImmunology, 2018
Na Luo, Luigi Formisano, Paula I. Gonzalez-Ericsson, Violeta Sanchez, Phillip T. Dean, Susan R. Opalenik, Melinda E. Sanders, Rebecca S. Cook, Carlos L. Arteaga, Douglas B. Johnson, Justin M. Balko
Interferon gamma (IFN-γ) is a soluble cytokine and the only member of the type-II interferon family. IFN-γ plays an important role in innate and adaptive immunity and also demonstrates anti-viral, immune-regulatory, and anti-tumor activity. IFN-γ is produced primarily by natural killer (NK) cells, natural killer T (NKT) cells, CD4 helper T cells, and CD8 cytotoxic T cells and initiates signaling by binding to a heterodimeric receptor composed of interferon gamma receptor 1 (IFNGR1) and interferon gamma receptor 2 (IFNGR2). After dimerized IFN-γ binds to its receptor, IFN-γ induces trans-phosphorylation and activation of JAK1 and JAK2. Activated JAK1/2 triggers the IFNGR to provide a STAT docking site through the SH2 domain and to recruit STATs to the JAK-IFNGR complex. After recruitment, STATs becomes activated and form dimers, allowing them to translocate to the nucleus to promote the expression of target genes involved in cell proliferation, differentiation and inflammation.9,10
Inhaled interferons beta and SARS-COV2 infection: a preliminary therapeutic perspective
Published in Expert Review of Respiratory Medicine, 2022
Elena Cojocaru, Cristian Cojocaru, Sabina Antonela Antoniu, Celina Silvia Stafie, Armand Rajnoveanu, Ruxandra-Mioara Rajnoveanu
IFN-β-1b has been shown to possess antiviral and immunomodulatory properties. Its biological properties are mediated by specific cellular receptors which induces the release of specific mediators, decreases affinity, stimulates the internalization, and degrades the interferon gamma receptor. Studies in healthy volunteers and rhesus monkeys did not reveal acute toxicity. Only few data are available for this compound as a monotherapy. In fact, case series of four critical patients with severe SARS-COV2 infection receiving another type of IFN-β, IFN-β-1b, and inhaled via cascade impactor to mimic the lung nebulization. Clinical improvements after 7–16 days of IFN dosing were reported along with the reduction in biomarkers of systemic inflammation [34].